febit Announces Operational Restructuring
febit today announced a restructuring as a consequence of its strategic focus on bloodbased microRNA biomarker discovery…
febit today announced a restructuring as a consequence of its strategic focus on bloodbased microRNA biomarker discovery…
febit today announced that an updated version of the company's Geniom Biochip containing 58 new discovered sequences in…
febit today announced the launch of its HybSelector, a new instrument for high throughput targeted resequencing, at the…
The Molecular Genetics Core Facility (MGCF) at Children's Hospital Boston chose febit's HybSelect technology which will…
febit's HybSelect has been recognized as one of the winners of the "Top 10 Innovations of 2009" by The Scientist magazin…
The Cancer Genomic Microarray Facility at the Kimmel Cancer Center of the Thomas Jefferson University, Philadelphia, sel…
Data published in BMC Cancer and PLoS ONE show that microRNA (miRNA) biomarkers provide reliable and highly differentiat…
febit's HybSelectTM technology for sequence capture enables targeted Next-Generation Sequencing, furthers development of…
115 of the most common cancer genes are now available for HybSelectâ, febit's highly automated technology for sequence c…
febit holding gmbh announced today the launch of the first biochip on the market covering the newly published whole mous…